Big Pharma to seek only selected generics opportunities, IMS predicts
This article was originally published in Scrip
Executive Summary
IMS Health made two significant predictions, among others, at the 13th annual International Generic Pharmaceutical Alliance (IGPA) conference in Mumbai. One was that Big Pharma is unlikely to emerge as a 'long-list' generics player, which appeared to be something that many in the audience anticipated and accepted.